{{'Search' | translate}}
 

Athymic Nude Mouse, Crl:NU(NCr)-Foxn1nu

Athymic Nude Mouse

Company: Charles River Laboratories
Catalog#: 490
Bio-protocol()
Company-protocol()
Other protocol()

A Novel Mouse Skin Graft Model of Vascular Tumors Driven by Akt1
Author:
Date:
2017-07-05
[Abstract]  To investigate whether endothelial Akt1 activation is sufficient to induce vascular tumor formation in the skin, we have developed a skin graft model in which a skin fragment from transgenic donor mice with inducible and endothelial cell-specific overexpression of activated Akt1 (myrAkt1) is grafted into the skin of wild type recipient mice. The donor skin successfully engrafts after two weeks and, more importantly, vascular tumor develops at the site of transgenic skin graft when myrAkt1 expression is turned on. This skin graft model is a novel approach to investigate the biological impact of a key signal transduction molecule in a temporal, localized and organ-specific manner. [摘要]  为了研究内皮Akt1的活化是否足以诱导皮肤血管肿瘤的形成,我们开发出一种皮肤移植模型,其中转基因供体小鼠的皮肤片段具有诱导型和内皮细胞特异性过度表达的活化的Akt1(myrAkt1)被移植入 野生型受体小鼠的皮肤。 供体皮肤在两周后成功植入,更重要的是,当myrAkt1表达被打开时,血管肿瘤发生在转基因皮肤移植物的位点。 这种皮肤移植模型是一种新颖的方法,以时间,局部和器官特异性方式研究关键信号转导分子的生物学影响。
【背景】我们的研究重点是调查Akt1在血管肿瘤发展中的作用。为了确定内皮细胞中Akt1的激活是否足以驱动血管瘤形成,我们开发并发表了一种血管肿瘤的皮肤移植模型(Phung et al。 ...

In vivo Efficacy Studies in Cell Line and Patient-derived Xenograft Mouse Models
Author:
Date:
2017-01-05
[Abstract]  In vivo xenograft models derived from human cancer cells have been a gold standard for evaluating the genetic drivers of cancer and are valuable preclinical models for evaluating the efficacy of cancer therapeutics. Recently, patient-derived tumorgrafts from multiple tumor types have been developed and shown to more accurately recapitulate the molecular and histological heterogeneity of cancer. Here we detail the procedures for developing patient-derived xenograft models from breast cancer tissue, cell-based xenograft models, serial tumor transplantation, tumor measurement, and drug treatment. [摘要]  衍生自人类癌细胞的体内异种移植模型已经成为评估癌症遗传学驱动因素的黄金标准,并且是用于评估癌症治疗药物功效的有价值的临床前模型。最近,已经开发了来自多种肿瘤类型的患者衍生的移植物,并且显示出更准确地概括了癌症的分子和组织学异质性。在这里,我们详细介绍了从乳腺癌组织,基于细胞的异种移植模型,连续肿瘤移植,肿瘤测量和药物治疗开发患者衍生异种移植模型的程序。

背景 异种移植模型已经成为研究癌症基因驱动因素和确定癌症治疗药物的潜在功效的有力方法。发现T细胞缺乏的无胸腺裸鼠(nu / nu)小鼠和T细胞和B细胞缺陷型严重联合免疫缺陷(scid / scid)小鼠(Flanagan, 1966; Bosma和Carroll,1991)。由于这些发现,其他免疫受损的小鼠模型已经变得可用,包括重组激活基因2(Rag2)敲除小鼠,非肥胖(NOD) - 小鼠和NOD-scid < il2rgamma(null)小鼠(也称为nsg小鼠)(shinkai等人,1992;="" prochazka等人,1992;="">
&nbsp;在开发包括注射或植入部位的异种移植模型时,应考虑几个选项。由于生长测量和成像的肿瘤可及性,皮下异种移植物通常用于体内研究;然而,该模型的显着限制是大多数癌细胞缺乏正常的基质微环境。原位异种移植物提供互补的基质微环境;然而,根据原位点,包括更复杂的外科手术,测量肿瘤生长或反应的难度以及啮齿动物基质的限制(Talmadge等人,2007),该途径也存在缺点。许多癌症研究尤其是乳腺癌研究中广泛应用原位异种移植物。注入乳腺脂肪垫是一个相对简单的程序,允许乳腺癌细胞的可见和可测量的生长。尽管乳腺脂肪垫为乳腺癌细胞提供了互补的组织部位,但重要的是注意到人和啮齿动物乳腺基质和激素环境之间存在明显差异。 ...

Comments